Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13896249 | 0.75 | HTR6 (0.51) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL13896218 | 0.75 | HTR6 (0.48) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL2319101 | 0.74 | HTR6 (0.57) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL16242806 | 0.74 | HTR6 (0.57) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL731798 | 0.74 | HTR6 (0.61) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL2026702 | 0.74 | HTR6 (0.57) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL29207366 | 0.73 | HTR6 (0.55) | HTR6CA1CA2MAOAMAOB | |
| Hydrochloric Acid SCHEMBL27814998 | 0.73 | HTR6 (0.59) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL11784556 | 0.71 | HTR6 (0.77) | HTR6CA1CA2MAOAMAOB | |
| SCHEMBL23832880 | 0.70 | HTR6 (0.53) | HTR6CA1CA2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-10053467-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-21 | — | — | US | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-9650349-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-05-16 | — | — | US | disclosed |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-11-26 | — | — | US | disclosed |
| US-9029397-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-05-12 | — | — | US | disclosed |
| US-8921399-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-12-30 | — | — | US | disclosed |
| US-20130053361-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-02-28 | — | — | US | disclosed |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2012-08-09 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| EP-2182809-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053361-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | HTR6 317/4885CA1 586/4885CA2 1979/4885 |
| US-10053467-B2 | Therapeutic isoxazole compounds | MAOB, MAOA, XDH | HTR6 317/4885CA1 586/4885CA2 1979/4885 |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | HTR6 317/4885CA1 586/4885CA2 1979/4885 |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | HTR6 317/4885CA1 586/4885CA2 1979/4885 |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | HTR6 317/4885CA1 586/4885CA2 1979/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | HTR6 317/4885CA1 586/4885CA2 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.